FDA Classifies Bone Infection Germ Detector as Safe Class II
Published Date: 5/12/2026
Rule
Summary
The FDA is officially classifying a new medical device that detects germs and their resistance markers in patients with possible bone infections as a Class II device, meaning it has special safety rules. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool, innovative tech. The classification is effective May 12, 2026, with the rules applying since April 29, 2022.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
New Diagnostic Access for Orthopedic Patients
The FDA officially placed a test that finds germs and resistance markers in suspected bone (orthopedic) infections into Class II, effective May 12, 2026 (applicable April 29, 2022). You may get faster access to this type of diagnostic test because FDA says the change will help patients get beneficial new devices by reducing regulatory burdens.
Easier Market Path for Future Devices
Because FDA classified this device via the De Novo process, the device can serve as a predicate for future tests of the same type, letting other companies use the less burdensome 510(k) process rather than De Novo or premarket approval. This change is intended to reduce regulatory burdens for device makers and may speed new, similar tests to market.
Manufacturers Must Meet Special Controls
Manufacturers placing this Class II device on the market must comply with the special controls in 21 CFR 866.3988 and submit a premarket notification under section 510(k). Required controls include using FDA-cleared/approved or 510(k)-exempt sample collection devices (or clearing the collection device with the test), specific labeling (intended use, limitations, device description), and design verification and validation with analytical studies (e.g., Limit of Detection, inclusivity, cross‑reactivity) and a clinical study using prospective samples for each claimed specimen type.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-09327, Official Seal
The Commodity Futures Trading Commission is rolling out a fresh new official seal featuring a bold navy background, a white eagle, and gold symbols of justice and peace. This update affects the Commission’s official look starting May 11, 2026, but won’t cost or change anything for the public. It’s all about giving the agency a sharp, modern identity!
Next: 2026-09375, Safety Zone; Seddon Channel, Tampa, FL
From May 18 to May 22, 2026, the Coast Guard is setting up a temporary safety zone in Seddon Channel, Tampa, to keep people and boats safe during the Special Operation Forces Week events. No one can enter this area without special permission, so boaters and visitors should plan ahead. This quick action helps prevent accidents during high-speed air and water activities near the Tampa Convention Center.